By Associate Professor Mandy Ballinger

Journal articles

Getachew R; Ballinger ML; Burch ML; Little PJ; Osman N, 2010, 'Characterisation of Ki11502 as a potent inhibitor of PDGF β receptor-mediated proteoglycan synthesis in vascular smooth muscle cells', European Journal of Pharmacology, 626, pp. 186 - 192, http://dx.doi.org/10.1016/j.ejphar.2009.09.066

Getachew R; Ballinger M; Burch M; Reid J; Khachigian LM, 2010, 'PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminologycan elongationon biglycan and increases binding to LDL.', Endocrinology, 151, pp. 4356 - 4367

Ballinger ML; Ivey ME; Osman N; Thomas WG; Little PJ, 2009, 'Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL', Atherosclerosis, 205, pp. 451 - 457, http://dx.doi.org/10.1016/j.atherosclerosis.2009.01.024

Yang SNY; Burch ML; Getachew R; Ballinger ML; Osman N; Little PJ, 2009, 'Growth factor-mediated hyper-elongation of glycosaminoglycan chains on biglycan requires transcription and translation', Archives of Physiology and Biochemistry, 115, pp. 147 - 154, http://dx.doi.org/10.1080/13813450903110754

Osman N; Ballinger ML; Dadlani HM; Getachew R; Burch ML; Little PJ, 2008, 'p38 MAP kinase mediated proteoglycan synthesis as a target for the prevention of atherosclerosis', Cardiovascular and Hematological Disorders - Drug Targets, 8, pp. 287 - 292, http://dx.doi.org/10.2174/187152908786786205

Ballinger ML; Osman N; Wilks AF; Su S; Burns CJ; Bu X; Little PJ, 2008, 'Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding', Journal of Cardiovascular Pharmacology, 52, pp. 403 - 412, http://dx.doi.org/10.1097/FJC.0b013e31818a8907

Dadlani H; Osman N; Ballinger ML; Marasco S; Little PJ, 2008, 'Calcific aortic valve disease and hypertension', Current Hypertension Reviews, 4, pp. 107 - 113, http://dx.doi.org/10.2174/157340208784245884

Dadlani H; Ballinger ML; Osman N; Getachew R; Little PJ, 2008, 'Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle', Journal of Biological Chemistry, 283, pp. 7844 - 7852, http://dx.doi.org/10.1074/jbc.M703125200

Little PJ; Ballinger ML; Survase S; Osman N; Ogru E; Geytenbeek S; Bruemmer D; Nigro J, 2008, 'Phosphorylated troglitazone activates PPARγ and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis', Journal of Cardiovascular Pharmacology, 51, pp. 274 - 279, http://dx.doi.org/10.1097/FJC.0b013e3181626ce7

Little PJ; Ballinger ML; Burch ML; Osman N, 2008, 'Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process.', Open Biochem J, 2, pp. 135 - 142, http://dx.doi.org/10.2174/1874091X00802010135

Little PJ; Osman N; de Dios ST; Cemerlang N; Ballinger M; Nigro J, 2007, 'Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: Thiazolidinediones (glitazones) have enhanced activity under high glucose conditions', Cardiovascular Diabetology, 6, http://dx.doi.org/10.1186/1475-2840-6-33

Grande-Allen KJ; Osman N; Ballinger ML; Dadlani H; Marasco S; Little PJ, 2007, 'Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease', Cardiovascular Research, 76, pp. 19 - 28, http://dx.doi.org/10.1016/j.cardiores.2007.05.014

Little PJ; Ballinger ML; Osman N, 2007, 'Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis', Vascular Health and Risk Management, 3, pp. 117 - 124

de Dios ST; Frontanilla KV; Nigro J; Ballinger ML; Ivey ME; Cawson EA; Little PJ, 2007, 'Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents', Journal of Diabetes and its Complications, 21, pp. 108 - 117, http://dx.doi.org/10.1016/j.jdiacomp.2006.03.003

Nigro J; Ballinger M; Osman N; Dart A; Little P, 2005, 'Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands', Current Cardiology Reviews, 1, pp. 89 - 102, http://dx.doi.org/10.2174/1573403054021654

Ballinger ML; Thomas MC; Nigro J; Ivey ME; Dilley RJ; Little PJ, 2005, 'Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells', Kidney International, 68, pp. 2756 - 2765, http://dx.doi.org/10.1111/j.1523-1755.2005.00746.x

Nigro J; Ballinger ML; Survase S; Osman N; Little PJ, 2005, 'New approaches to regulating the chondroitin/dermatan sulfate glycosaminoglycan component of the vascular extracellular matrix.', TheScientificWorldJournal, 5, pp. 515 - 520, http://dx.doi.org/10.1100/tsw.2005.69

Nigro J; Ballinger ML; Dilley RJ; Jennings GLR; Wight TN; Little PJ, 2004, 'Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding', Diabetologia, 47, pp. 2105 - 2113, http://dx.doi.org/10.1007/s00125-004-1588-z

Ballinger ML; Nigro J; Frontanilla KV; Dart AM; Little PJ, 2004, 'Regulation of glycosaminoglycan structure and atherogenesis', Cellular and Molecular Life Sciences, 61, pp. 1296 - 1306, http://dx.doi.org/10.1007/s00018-004-3389-4

Back to profile page